# South Korea Microbiome Sequencing Services Market > South Korea Microbiome Sequencing Services Market Research Report: By Technology (Sequencing by Litigation (SBL), Sequencing by Synthesis (SBS), Short Gun Sequencing, Targeted Gene Sequencing, RNA Sequencing, Others) andBy Application (Gastrointestinal Diseases, Infectious Diseases, CNS Diseases, Oncology, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 15.33% - **2024:** $ 62.5 Million - **2025:** $ 72.08 Million - **2035:** $ 300 Million - **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Zymo Research (US), Qiagen (DE), Genomatix (DE), Microbiome Insights (CA), Second Genome (US), CosmosID (US) **Report ID:** MRFR/HC/52145-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-microbiome-sequencing-services-market-53907 --- ## Market Summary ## **South Korea Microbiome Sequencing Services Market Overview****:** As per MRFR analysis, the South Korea Microbiome Sequencing Services Market Size was estimated at 47.32 (USD Million) in 2023. The South Korea Microbiome Sequencing Services Market Industry is expected to grow from 52(USD Million) in 2024 to 366 (USD Million) by 2035. The South Korea Microbiome Sequencing Services Market CAGR (growth rate) is expected to be around 19.411% during the forecast period (2025 - 2035). ### **Key South Korea Microbiome Sequencing Services Market Trends Highlighted** The South Korea Microbiome Sequencing Services Market is experiencing significant trends as a result of the growing interest in personalized medicine and advanced genomics research. The increasing recognition of the human microbiome's function in health and disease is a significant market driver, inducing a demand for microbiome analysis in clinical settings. Innovations in microbiome sequencing services have been further facilitated by the South Korean government's support of biotechnology research and development.  The Korea Biobank and other organizations facilitate research endeavors and the comprehension of the microbiome's implications in a variety of health conditions by providing access to biological samples. Opportunities are arising in the health and wellness sector, with a particular emphasis on the development of probiotic products and nutritional genomics. The government initiatives that advocate for health improvement through biotechnology innovations have identified a substantial opportunity for companies to offer customized microbiome analysis services that address personal dietary requirements and gut health as consumers become more health-conscious. Collaborations between academic institutions and private enterprises, which are designed to facilitate the advancement of microbiome research, have also been emphasized in recent trends.  The advancement of novel sequencing technologies and data analysis methods is fostered by South Korea's commitment to becoming a biotechnology leader, which provides a conducive environment for these partnerships.In addition, there is a growing interest in the application of microbiome data in the disciplines of environmental science and agriculture, with research endeavors focusing on sustainable practices that capitalize on the comprehension of microbial communities. These dynamics suggest that the microbiome sequencing landscape in South Korea is dynamic and constantly changing. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **South Korea Microbiome Sequencing Services Market Drivers** ### **Increasing Demand for Personalized Medicine** The South Korea Microbiome Sequencing Services Market Industry is witnessing a significant rise in demand for personalized medicine, propelled by advancements in genomics and biotechnology. The country's healthcare sector is increasingly shifting towards tailored therapies, leading to a surge in microbiome research, which is crucial for understanding individual health complexities. According to the Korean Ministry of Health and Welfare, investments in personalized healthcare solutions have seen a consistent annual growth of approximately 15% over the last three years.Companies such as LG Chem and Samsung Biologics are heavily investing in Research and Development (R&D) for microbiome-related therapies, further supporting this driver. As more clinical trials and studies focus on the microbiome's role in various diseases, the demand for microbiome sequencing services is expected to escalate significantly. ### **Rising Incidence of Metabolic Disorders** The increasing prevalence of metabolic disorders in South Korea is becoming a crucial driver for the South Korea Microbiome Sequencing Services Market Industry. A report from the Korean Diabetes Association indicates that the incidence of diabetes has risen by 10% over the last three years, affecting millions. Such health challenges necessitate the exploration of microbiome alterations that may contribute to metabolic dysfunctions. Major healthcare institutions in South Korea, like Seoul National University Hospital, are conducting cutting-edge research to link microbiome composition with metabolic diseases, driving demand for sequencing services.This focus on personalized metabolic health solutions is expected to promote growth within this segment. ### **Government Initiatives Supporting Biotechnology** The South Korean government is actively promoting the biotechnology sector, significantly impacting the South Korea Microbiome Sequencing Services Market Industry. Recent policies, including the 'Bio-Vision 2030' initiative, aim to enhance the biotechnology ecosystem through funding and support for innovative biotech companies, including those focusing on microbiome research. The government has earmarked over 1 trillion Korean Won for biotechnology development, emphasizing microbiome applications in health and agriculture.Established firms like CJ CheilJedang are responding to this supportive policy environment by accelerating their microbiome-centric projects, thus driving the need for sequencing services in the region. Increased government backing is projected to exponentially boost market growth over the coming years. ## **South Korea Microbiome Sequencing Services Market Segment Insights****:** ### **Microbiome Sequencing Services Market Technology Insights** The South Korea Microbiome Sequencing Services Market under the Technology segment is experiencing significant evolution, driven by advancements in genomics and computational methodologies. Sequencing technologies such as Sequencing by Litigation (SBL) and Sequencing by Synthesis (SBS) are at the forefront, enabling detailed analysis of microbial communities and their functionalities. These platforms enhance the accuracy and speed of sequencing, making them crucial for both Research and Development and clinical applications.  Short Gun Sequencing offers the advantage of producing comprehensive genomic data by randomly sequencing DNA fragments, thereby revealing a broader spectrum of microbial diversity.This technique is particularly important in understanding complex microbiomes, which can influence health and disease states. Furthermore, Targeted Gene Sequencing provides researchers and healthcare professionals with the ability to focus on specific genes of interest, facilitating deeper insights into microbial functions and their implications in various medical conditions.  RNA Sequencing, on the other hand, plays a pivotal role in examining gene expression profiles, aiding in the understanding of how microbiomes respond to environmental changes or therapeutic interventions.Coupled with advancements in bioinformatics, these technologies collectively cater to the burgeoning demand for microbiome research, offering opportunities for personalized medicine and novel therapeutic strategies. The continuous evolution of these sequencing technologies signifies their growing importance in South Korea's biotechnology landscape, echoing the nation’s commitment to developing innovative health solutions. In this context, others in the spectrum also contribute to the dynamic nature of the market, accommodating various research needs and genetic inquiries.The integration of these cutting-edge technologies is expected to remain pivotal as the market continues to mature, aligning with South Korea's strategic objectives in the biomedical field. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Microbiome Sequencing Services Market Application Insights** The Application segment of the South Korea Microbiome Sequencing Services Market plays a crucial role in enhancing healthcare outcomes through its diverse fields. This segment encompasses various areas, with Gastrointestinal Diseases being notably significant as they are highly prevalent in the region, influencing dietary and overall health. Infectious Diseases are pivotal due to the growing need for rapid diagnostics and personalized treatments, particularly as microbial resistance becomes a pressing concern globally.  Central Nervous System (CNS) Diseases are gaining attention as research shows links between gut microbiota and mental health, driving interest in innovative therapeutic approaches.Oncology also stands out, as the microbiome can impact cancer treatment efficacy and patient responses, fostering research into personalized therapies. Additionally, the Others category includes emerging applications exploring the microbiome's role in metabolic functions and autoimmune disorders, highlighting the potential for further discovery and innovation. The South Korea Microbiome Sequencing Services Market segmentation thus reflects not only the existing medical landscape but also the future directions of medical research and therapeutic development in the country. ## **South Korea Microbiome Sequencing Services Market Key Players and Competitive Insights****:** The South Korea Microbiome Sequencing Services Market is characterized by a rapidly evolving landscape driven by technological advancements and increasing interest in personalized medicine and health. The competitive dynamics in this market have seen the emergence of key players who leverage cutting-edge sequencing technologies and comprehensive bioinformatics services.  This market is fueled by the rising awareness of the microbiome's role in human health, agriculture, and drug development, thus catalyzing investments from various sectors including healthcare, biotechnology, and pharmaceuticals. Players in this space are focused on enhancing their service offerings, optimizing operational efficiencies, and expanding their geographical footprints to tap into the growing demand for microbiome analysis.PerkinElmer has established a strong presence in the South Korea Microbiome Sequencing Services Market by offering a range of innovative services that cater to the diverse needs of researchers and clinicians.  The company excels in providing advanced genomics and bioinformatics solutions that are crucial for in-depth microbiome analysis. Its robust portfolio includes proprietary technologies that enhance the accuracy and efficiency of microbiome sequencing, solidifying its reputation as a leader in the field. Furthermore, PerkinElmer's commitment to fostering collaborations with research institutions and healthcare providers in South Korea demonstrates its strategic approach to enhance service delivery and expand its customer base.  The company’s substantial investments in R&D enable it to stay at the forefront of microbiome sequencing innovations, thereby reinforcing its competitive advantage in this burgeoning market.Zymo Research has made substantial strides within the South Korea Microbiome Sequencing Services Market, offering a wide array of products and services designed to facilitate microbiome research. Known for its comprehensive collection of sample preparation kits, sequencing reagents, and data analysis tools, Zymo Research has positioned itself as a vital partner for researchers exploring the complexities of microbiomes.  The company's strengths lie in its high-quality standards and reliable service, which have garnered a loyal customer base among academic and industry researchers in South Korea. Moreover, Zymo Research has made strategic investments aimed at expanding its capabilities, including partnerships and collaborations to enhance its service offerings further. While specifics regarding mergers and acquisitions may not be disclosed, the company's continuous growth and innovation strategy enable it to adapt quickly to changing market demands, ensuring that it remains a key player in the microbiome sequencing sector within South Korea. ### **Key Companies in the South Korea Microbiome Sequencing Services Market Include:** - PerkinElmer - Zymo Research - Macrogen - Roche - Ginkgo Bioworks - Thermo Fisher Scientific - Illumina - BGI - SciGenom Labs - Novogene - Oxford Nanopore Technologies - Fast Genetics - Genomatix ## **South Korea Microbiome Sequencing Services Market Industry Developments** Recent developments in the South Korea Microbiome Sequencing Services Market have highlighted notable advancements and partnerships within the industry. Companies like PerkinElmer and Thermo Fisher Scientific have been expanding their offerings to enhance microbiome analysis capabilities, catering to increased demand from healthcare and research sectors. In September 2023, Macrogen announced its collaboration with Illumina to leverage next-generation sequencing technologies for more comprehensive microbiome research. Additionally, significant growth has been observed in the market valuation of companies such as Ginkgo Bioworks and BGI, driven by increased funding in biotechnology and demand for microbiome-related health solutions.   In terms of mergers and acquisitions, a noteworthy transaction occurred in August 2023 when Roche acquired a minority stake in Genomatix, focusing on integrating genomic data processing and microbiome insights for precision medicine applications. The South Korean government has also been encouraging investments in biotechnological R&D initiatives, establishing favorable conditions for companies engaged in microbiome research and sequencing. Overall, these developments reflect a rapidly evolving landscape where competitive dynamics and technological advancements are reshaping the South Korean microbiome market. ## **South Korea Microbiome Sequencing Services Market Segmentation Insights** ### **Microbiome Sequencing Services Market Technology****Outlook** - Sequencing by Litigation (SBL) - Sequencing by Synthesis (SBS) - Short Gun Sequencing - Targeted Gene Sequencing - RNA Sequencing - Others ### **Microbiome Sequencing Services Market Application****Outlook** - Gastrointestinal Diseases - Infectious Diseases - CNS Diseases - Oncology - Others ## Market Drivers ### Increased Research Funding In South Korea, the microbiome sequencing-services market is benefiting from heightened research funding from both government and private sectors. The South Korean government has recognized the potential of microbiome research in addressing various health issues, allocating substantial budgets to support studies in this field. For instance, funding for microbiome-related projects has seen an increase of over 30% in recent years. This financial backing is facilitating advancements in sequencing technologies and methodologies, making them more accessible to researchers and healthcare professionals. As a result, the volume of microbiome studies is expected to rise, further driving the demand for sequencing services. The influx of funding is likely to stimulate innovation and collaboration among academic institutions and industry players, thereby enhancing the overall landscape of the microbiome sequencing-services market. ### Growing Interest in Gut Health The rising awareness of gut health among the South Korean population is significantly influencing the microbiome sequencing-services market. Consumers are increasingly recognizing the connection between gut microbiota and overall health, leading to a surge in demand for microbiome testing services. This trend is reflected in the growing market for probiotics and prebiotics, which are often marketed based on their effects on gut health. As individuals seek to optimize their microbiomes for better health outcomes, the demand for sequencing services is expected to rise. Additionally, educational campaigns and health initiatives promoting gut health are likely to further enhance consumer interest in microbiome analysis. This growing focus on gut health presents a substantial opportunity for the microbiome sequencing-services market to expand and innovate. ### Rising Incidence of Chronic Diseases The escalating prevalence of chronic diseases in South Korea is a significant driver for the microbiome sequencing-services market. Conditions such as obesity, diabetes, and gastrointestinal disorders are increasingly being linked to microbiome imbalances. As healthcare providers seek to understand the underlying causes of these diseases, the demand for microbiome analysis is expected to surge. Recent studies suggest that approximately 40% of the South Korean population may be affected by chronic diseases, highlighting the urgent need for effective diagnostic and therapeutic solutions. This trend is likely to encourage healthcare professionals to incorporate microbiome sequencing into routine clinical practice, thereby expanding the market. The potential for microbiome-based interventions to improve health outcomes further underscores the importance of this market in addressing public health challenges. ### Technological Innovations in Sequencing Technological advancements in sequencing technologies are playing a pivotal role in shaping the microbiome sequencing-services market in South Korea. Innovations such as next-generation sequencing (NGS) and metagenomics are enhancing the accuracy and efficiency of microbiome analysis. These technologies allow for comprehensive profiling of microbial communities, providing valuable insights into their roles in health and disease. The cost of sequencing has also decreased significantly, making it more accessible to researchers and clinicians. As a result, the adoption of these advanced technologies is expected to increase, driving the growth of the microbiome sequencing-services market. Furthermore, the development of user-friendly bioinformatics tools is likely to facilitate data interpretation, thereby attracting more stakeholders to invest in microbiome research and services. ### Growing Demand for Personalized Medicine The increasing emphasis on personalized medicine in South Korea is driving the microbiome sequencing-services market. As healthcare shifts towards tailored treatments, understanding individual microbiomes becomes crucial. This trend is reflected in the rising investments in microbiome research, with the market projected to reach approximately $500 million by 2027. Personalized approaches to health management, including diet and medication, are gaining traction, leading to a greater need for microbiome analysis. The integration of microbiome data into clinical practices is expected to enhance patient outcomes, thereby propelling the demand for sequencing services. Furthermore, collaborations between biotech firms and healthcare providers are likely to foster innovation in this sector, indicating a robust growth trajectory for the microbiome sequencing-services market. ## Future Outlook The [Microbiome Sequencing Services Market](https://www.marketresearchfuture.com/reports/microbiome-sequencing-services-market-7532) is projected to grow at a 15.33% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increasing health awareness, and technological innovations. **New opportunities:** - Development of subscription-based microbiome analysis services for consumers. - Partnerships with healthcare providers for integrated microbiome health solutions. - Investment in AI-driven data analytics for enhanced microbiome interpretation. By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in health innovation. ## Segment Insights ### By Technology: Sequencing by Synthesis (Largest) vs. RNA Sequencing (Fastest-Growing) In the South Korea microbiome sequencing-services market, Sequencing by Synthesis (SBS) stands out as the largest segment, commanding a significant market share due to its established technological framework and widespread adoption across various applications. Following closely, Sequencing by Litigation (SBL) and targeted gene sequencing also hold notable shares, contributing to a diversified market landscape. Short Gun Sequencing, while important, retains a smaller presence compared to other dominant forms of sequencing. The growth trends in this segment indicate a robust inclination towards RNA Sequencing as the fastest-growing technology, driven by advancements in genomics and increasing demand for RNA-based research in healthcare and personalized medicine. Innovations in sequencing accuracy and cost-efficiency further bolster the adoption of these technologies, hinting at a future where multi-omics approaches become standard in clinical and research settings. Furthermore, the increasing investments in biotechnology research are expected to expand the market opportunities for all technologies significantly. Technology: Sequencing by Synthesis (Dominant) vs. RNA Sequencing (Emerging) Sequencing by Synthesis (SBS) is the dominant technology in the South Korea microbiome sequencing-services market, revered for its high-throughput capabilities and reliable results. This method powers a significant proportion of genomic studies, benefiting from years of development and user familiarity. Conversely, RNA Sequencing, classified as an emerging yet rapidly growing segment, caters to the need for understanding transcriptional responses in various biological contexts. Its adoption is rising in tandem with the burgeoning interest in transcriptomics, driven by the healthcare sector's quest for tailored therapeutic solutions. Both segments showcase unique strengths; SBS focuses on broader genomic sequencing needs while RNA Sequencing paves the way for specialized insights into gene activity, setting the stage for a dynamic evolution within the market. ### By Application: Gastrointestinal Diseases (Largest) vs. Oncology (Fastest-Growing) In the South Korea microbiome sequencing-services market, the application segment is prominently led by Gastrointestinal Diseases, which commands a substantial share due to the rising prevalence of digestive disorders among the population. Following closely are Infectious Diseases and Oncology, which are also gaining traction as awareness of microbial impacts on health increases. The allocation of market share among these applications showcases the versatility of microbiome sequencing in addressing critical health issues. Growth trends reflect the accelerating pace of innovation in microbiome research and its applications, particularly in Oncology, where tailored therapies are reshaping treatment paradigms. The increasing investment by biotech firms and healthcare institutions is driving advancements in sequencing technologies, fostering a pipeline of services. Additionally, the rising focus on preventive healthcare and personalized medicine with microbiome insights is propelling market growth. Gastrointestinal Diseases (Dominant) vs. Oncology (Emerging) Gastrointestinal Diseases represent the dominant application in the South Korea microbiome sequencing-services market, characterized by extensive research and established treatment protocols. This segment benefits from a robust understanding of gut health's correlation with overall well-being, positioning it favorably in clinical practices. Conversely, Oncology is emerging rapidly as a significant focus area due to ongoing research into the microbiome's role in cancer therapies. The integration of microbiome profiles into oncological assessments signifies its potential to enhance treatment outcomes. Together, these segments reflect the diverse applicability of microbiome sequencing, with Gastrointestinal Diseases leading traditionally while Oncology shows promising growth trajectories. ## Competitive Benchmarking The microbiome sequencing-services market in South Korea is characterized by a dynamic competitive landscape, driven by advancements in technology and increasing demand for personalized medicine. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Qiagen (DE) are at the forefront, leveraging their extensive research capabilities and innovative product offerings. Illumina (US) focuses on enhancing its sequencing platforms, while Thermo Fisher Scientific (US) emphasizes integration of its services with clinical applications. Qiagen (DE) is strategically positioned through its robust bioinformatics solutions, which complement its sequencing services. Collectively, these strategies foster a competitive environment that prioritizes innovation and technological advancement, thereby shaping market dynamics.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set industry standards and drive technological advancements. This competitive structure encourages smaller firms to innovate and differentiate their offerings, contributing to a vibrant market ecosystem. In October Illumina (US) announced a partnership with a leading South Korean healthcare provider to develop tailored microbiome sequencing solutions aimed at improving patient outcomes. This collaboration is significant as it not only expands Illumina's footprint in the region but also aligns with the growing trend of personalized healthcare, potentially enhancing patient engagement and treatment efficacy. In September Thermo Fisher Scientific (US) launched a new suite of microbiome analysis tools designed to streamline research processes for academic and clinical laboratories. This strategic move is indicative of the company's commitment to innovation and positions it favorably against competitors by offering cutting-edge solutions that meet the evolving needs of researchers. In August Qiagen (DE) unveiled a new bioinformatics platform that integrates with its sequencing services, allowing for more comprehensive data analysis. This development is crucial as it enhances the value proposition of Qiagen's offerings, enabling customers to derive actionable insights from their microbiome data, thus reinforcing its competitive edge in the market. As of November current trends in the microbiome sequencing-services market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in data analysis. Strategic alliances among key players are increasingly shaping the competitive landscape, fostering innovation and collaboration. Looking ahead, it is anticipated that competitive differentiation will evolve, with a greater emphasis on technological innovation and supply chain reliability, moving away from traditional price-based competition. This evolution underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive advantage. ## Recent News & Developments Recent developments in the South Korea Microbiome Sequencing Services Market have highlighted notable advancements and partnerships within the industry. Companies like PerkinElmer and Thermo Fisher Scientific have been expanding their offerings to enhance microbiome analysis capabilities, catering to increased demand from healthcare and research sectors. In September 2023, Macrogen announced its collaboration with Illumina to leverage next-generation sequencing technologies for more comprehensive microbiome research. Additionally, significant growth has been observed in the market valuation of companies such as Ginkgo Bioworks and BGI, driven by increased funding in biotechnology and demand for microbiome-related health solutions.   In terms of mergers and acquisitions, a noteworthy transaction occurred in August 2023 when Roche acquired a minority stake in Genomatix, focusing on integrating genomic data processing and microbiome insights for precision medicine applications. The South Korean government has also been encouraging investments in biotechnological R&D initiatives, establishing favorable conditions for companies engaged in microbiome research and sequencing. Overall, these developments reflect a rapidly evolving landscape where competitive dynamics and technological advancements are reshaping the South Korean microbiome market. ## Report Scope | MARKET SIZE 2024 | 62.5(USD Million) | | --- | --- | | MARKET SIZE 2025 | 72.08(USD Million) | | MARKET SIZE 2035 | 300.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 15.33% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Zymo Research (US), Qiagen (DE), Genomatix (DE), Microbiome Insights (CA), Second Genome (US), CosmosID (US) | | Segments Covered | Technology, Application | | Key Market Opportunities | Rising demand for personalized medicine drives growth in the microbiome sequencing-services market. | | Key Market Dynamics | Rising demand for personalized medicine drives innovation in microbiome sequencing-services within South Korea's healthcare sector. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What is the current valuation of the microbiome sequencing-services market in South Korea?** A: The market valuation was $62.5 Million in 2024. **Q: What is the projected market size for the microbiome sequencing-services market by 2035?** A: The market is projected to reach $300.0 Million by 2035. **Q: What is the expected CAGR for the microbiome sequencing-services market during the forecast period 2025 - 2035?** A: The expected CAGR is 15.33% during the forecast period. **Q: Which companies are the key players in the microbiome sequencing-services market?** A: Key players include Illumina, Thermo Fisher Scientific, Zymo Research, Qiagen, Genomatix, Microbiome Insights, Second Genome, and CosmosID. **Q: What are the main technology segments in the microbiome sequencing-services market?** A: Main technology segments include Sequencing by Litigation, Sequencing by Synthesis, Short Gun Sequencing, Targeted Gene Sequencing, RNA Sequencing, and Others. **Q: What is the valuation range for Sequencing by Synthesis in the market?** A: The valuation range for Sequencing by Synthesis is $15.0 Million to $75.0 Million. **Q: Which application segment has the highest valuation in the microbiome sequencing-services market?** A: The Oncology application segment has the highest valuation, ranging from $15.0 Million to $80.0 Million. **Q: What is the valuation range for Gastrointestinal Diseases in the application segment?** A: The valuation range for Gastrointestinal Diseases is $12.5 Million to $60.0 Million. **Q: How does the market for microbiome sequencing-services in South Korea compare to other regions?** A: While specific regional comparisons are not provided, the growth trajectory suggests a robust market potential in South Korea. **Q: What are the implications of the projected growth for stakeholders in the microbiome sequencing-services market?** A: The projected growth indicates potential opportunities for investment and innovation among stakeholders in the market. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-microbiome-sequencing-services-market-53907*